With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline ...

Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...

In the Phase III results, Ziihera plus immunotherapy and chemo improved survival outcomes compared to Herceptin plus chemo.

Novamigra Therapeutics secures ~€3 million funding to advance first-in-human Phase 1 study of its migraine prophylaxis ...

Eli Lilly said Ventyx’s pipeline has potential applications in cardiometabolic health, neurodegeneration, and autoimmunity.

First-in-human study evaluates safety, pharmacokinetics, biomarker analyses, target engagement, and anti-tumor activity in patients with advanced ...

Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of ...

Insmed outlines 2026 outlook, highlighting BRINSUPRI expansion, ARIKAYCE revenue guidance and multiple late-stage clinical ...

Our environmental team has identified the location as habitat for Spotted Owl and Marbled Murrelet,” the agency said.

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).